Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE)
This research protocol will evaluate subjects with systemic lupus erythematosus (SLE) and their relatives to study the pathogenesis and natural history of the disease and the mechanisms leading to enhanced organ damage. Patients will be evaluated by a history and physical examination and routine laboratory studies will be obtained as needed to assess disease activity or complications of the disease and to monitor for drug-related toxicities. Blood, skin or urine specimens may be requested for research purposes, including genetic studies. In addition, a subset of these patients will undergo several tests to understand the pathogenic changes affecting their blood vessels. Patients who are eligible for other research protocols will be offered the opportunity to participate in these studies by signed informed consent. Any medical care recommended or provided to the patient will be consistent with routine standards of practice and provided in consultation with the patient s referring physician. Blood and urine samples and cardiovascular testing will also be collected or performed on healthy volunteers for research purposes and to support the identification and validation of new biomarker candidates..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
August 22, 2018 |
|---|---|
| Erschienen: |
Bethesda (Maryland): ClinicalTrials.gov ; August 22, 2018 |
| Sprache: |
Englisch |
|---|
| Körperschaft: |
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [Herausgebendes Organ] |
|---|
| Links: |
|---|
| Themen: |
Clinical Study |
|---|
| Weitere IDs: |
940066 94-AR-0066 NCT00001372 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1039884210 |
|---|
| LEADER | 01000cam a2200265 4500 | ||
|---|---|---|---|
| 001 | 1039884210 | ||
| 003 | DE-627 | ||
| 005 | 20230905071253.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181106s2018 xx |||||o 00| ||eng c | ||
| 024 | 8 | |a 940066 |q Other Study ID Numbers | |
| 024 | 8 | |a 94-AR-0066 |q Other Study ID Numbers | |
| 024 | 8 | |a NCT00001372 |q Other Study ID Numbers | |
| 035 | |a (DE-627)1039884210 | ||
| 035 | |a (DE-599)GBV1039884210 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE) |
| 264 | 1 | |a Bethesda (Maryland) |b ClinicalTrials.gov |c August 22, 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a This research protocol will evaluate subjects with systemic lupus erythematosus (SLE) and their relatives to study the pathogenesis and natural history of the disease and the mechanisms leading to enhanced organ damage. Patients will be evaluated by a history and physical examination and routine laboratory studies will be obtained as needed to assess disease activity or complications of the disease and to monitor for drug-related toxicities. Blood, skin or urine specimens may be requested for research purposes, including genetic studies. In addition, a subset of these patients will undergo several tests to understand the pathogenic changes affecting their blood vessels. Patients who are eligible for other research protocols will be offered the opportunity to participate in these studies by signed informed consent. Any medical care recommended or provided to the patient will be consistent with routine standards of practice and provided in consultation with the patient s referring physician. Blood and urine samples and cardiovascular testing will also be collected or performed on healthy volunteers for research purposes and to support the identification and validation of new biomarker candidates. | ||
| 540 | |a Nutzungsrecht: Source: ClinicalTrials.gov (no modifications made) | ||
| 540 | |a ClinicalTrials.gov processed this data on October 23, 2018 | ||
| 540 | |a Last update posted on ClinicalTrials.gov: August 22, 2018 | ||
| 540 | |a Last updated: 2018-11-06 | ||
| 650 | 2 | |a Clinical Study | |
| 650 | 2 | |a Lupus Erythematosus, Systemic | |
| 650 | 2 | |a Observational Study | |
| 650 | 4 | |a Clinical Study Status: Recruiting | |
| 650 | 4 | |a Systemic Lupus Erythematosus | |
| 650 | 4 | |a Natural History | |
| 650 | 4 | |a Lupus Nephritis | |
| 650 | 4 | |a Lupus | |
| 650 | 4 | |a Systemic Lupus | |
| 650 | 4 | |a SLE | |
| 710 | 2 | |a National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |e Herausgebendes Organ |4 isb | |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT00001372 |x Verlag |3 Volltext |
| 912 | |a GBV_ILN_20 | ||
| 912 | |a ISIL_DE-84 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-DE-84 | ||
| 951 | |a BO | ||
| 980 | |2 20 |1 01 |x 0084 |b 1824465866 |k Source: ClinicalTrials.gov (no modifications made) |k ClinicalTrials.gov processed this data on October 23, 2018 |k Last update posted on ClinicalTrials.gov: August 22, 2018 |k Last updated: 2018-11-06 |y z |z 06-11-18 | ||